Highlights and Introduction

• Allegiance Equity Corporation (Allegiance) Toronto Stock Exchange –ANQ (Venture) (TSX-ANQ(V)) was incorporated in 1974 and has been a reporting issuer for over 30 years.



• There are approximately 600 shareholders and 4,295,000 shares issued and outstanding since 1974.



• Allegiance has developed a unique expertise in creating new important treatments for widespread diseases where existing drugs and Over The Counter (OTC) products fail to meet the needs of patients.



• Allegiances assets include large equity positions in companies that have developed dramatic new treatments in fields of dermatology, diabetes, high cholesterol and related cardiovascular conditions.



• Allegiance will grow by expanding its interest in the development and formulation of dramatic new treatments for cardiovascular diseases.



• Our portfolio of effective proprietary treatments with proven advantages over multi billion dollar drugs, such as Liptor, Dovenex, Crestor, etc., in the field of dermatology, diabetes, high cholesterol and cardiovascular disease have the potential to increase the value of Allegiance by several hundred millions of dollars.



• In summary, Allegiance also holds a valuable 1.5% net smelter return and first rights of refusal to acquire 32 strategically located mining claims adjacent to mines that have produced 24 million ounces of gold and where Kirkland Lake Gold Inc. has made dramatic new discoveries.
  

"Allegiance" assists emerging technology businesses to finance their operations by providing consulting services in exchange for valuable equity positions.

Allegiance specializes in providing its unique experts in the biotech and pharmaceutical industry, where the development of drugs including Tiazac® (Biovail) , An-1792® (Elan), Viagra® (Pfizer), and Celexa® (Forest Labs) have increased shareholder value and revenues by several hundred millions to several billions of dollars.

Allegiance focuses on companies that target billion dollar markets having clearly identified product deficiencies and dissatisfied patients who suffer widespread diseases and conditions including diabetes, high cholesterol, cardiovascular deterioration and arthritis.

Allegiance’s strategy utilizes leading edge scientific technology to create valuable, proprietary and effective natural treatments, recognized as safe and effective by North America regulatory authorities, at a fraction of the cost and time it takes to develop a prescription drug.

Allegiance competencies are product development plus effective sales and marketing strategies. All non-revenue producing activities such as manufacturing, distribution and research will be outsourced in order to minimize costs and maximize financial flexibility.

From an investment point of view OTC products hold significant advantages over prescription drugs. OTC products require less capital to develop and there are few if any safety issues. The result is far less financial, safety and legal risk. The time cycle to develop and market an OTC product and generate revenue is less than a year, compared to five to ten years for a prescription drug.